Dynavax Technologies Corporation – Product Pipeline Review – Q1 2011 by GlobalMarketsDirect

VIEWS: 16 PAGES: 61

More Info
									Dynavax Technologies Corporation – Product Pipeline
                Review – Q1 2011
                                                                                          Reference Code: GMDHC1279CDB

                                                                                                Publication Date: JUN 2011




Dynavax Technologies Corporation – Product Pipeline Review – Q1 2011                        GMDHC1279CDB / Published JUN 2011

© Global Markets Direct. This report is a licensed product and is not to be photocopied                                Page(1)
Dynavax Technologies Corporation – Product Pipeline Review




Ta b le o f Co n te n ts
Table of Contents                                                                                                     2
List of Tables                                                                                                        4
List of Figures                                                                                                       4
Dynavax Technologies Corporation Snapshot                                                                             5
    Dynavax Technologies Corporation Overview                                                                         5
    Key Information                                                                                                   5
    Key Facts                                                                                                         5
Dynavax Technologies Corporation – Research and Development Overview                                                  6
    Key Therapeutic Areas                                                                                             6
Dynavax Technologies Corporation – Pipeline Review                                                                    8
    Pipeline Products by Stage of Development                                                                         8
    Pipeline Products – Monotherapy                                                                                   9
    Pipeline Products – Combination Treatment Modalities                                                             10
Dynavax Technologies Corporation – Pipeline Products Glance                                                          11
    Dynavax Technologies Corporation – Late Stage Pipeline                                                           11
         Phase III Products/Combination Treatment Modalities                                                         11
    Dynavax Technologies Corporation Clinical Stage Pipeline Products                                                12
         Phase I Products/Combination Treatment Modalities                                                           12
    Dynavax Technologies Corporation–Early Stage Pipeline Products                                                   13
         Pre-Clinical Products/Combination Treatment Modalities                                                      13
Dynavax Technologies Corporation – Drug Profiles                                                                     14
    Heplisav                                                                                                         14
         Product Description                                                                                         14
         Mechanism of Action                                                                                         14
         R&D Progress                                                                                                14
    DV-1179                                                                                                          16
         Product Description                                                                                         16
         Mechanism of Action                                                                                         16
         R&D Progress                                                                                                16
    DV-601                                                                                                           17
         Product Description                                                                                         17
         Mechanism of Action                                                                                         17
         R&D Progress                                                                                                17
    N8295                                                                                                            18
         Product Description                                                                                         18
         Mechanism of Action                                                                                         18
         R&D Progress                                                                                                18
    SD-101                                                                                                           19
         Product Description                                                                                         19
         Mechanism of Action                                                                                         19
         R&D Progress                                                                                                19
    SD-101 + Ribavirin                                                                                               20
         Product Description                                                                                         20
         Mechanism of Action                                                                                         20
         R&D Progress                                                                                                20
    DV-1179                                                                                                          21




Dynavax Technologies Corporation – Product Pipeline Review – Q1 2011                      GMDHC1279CDB / Published JUN 2011

©Global Markets Direct.. This report is a licensed product and is not to be photocopied                             Page(2)
Dynavax Technologies Corporation – Product Pipeline Review



         Product Description                                                                                             21
         Mechanism of Action                                                                                             21
         R&D Progress                                                                                                    21
    DV1079                                                                                                               22
         Product Description                                                                                             22
         Mechanism of Action                                                                                             22
         R&D Progress                                                                                                    22
    IRS 954                                                                                                              23
         Product Description                                                                                             23
         Mechanism of Action                                                                                             23
         R&D Progress                                                                                                    23
Dynavax Technologies Corporation – Pipeline Analysis                                                                     24
    Dynavax Technologies Corporation – Pipeline Products by Therapeutic Class                                            24
    Dynavax Technologies Corporation - Pipeline Products By Target                                                       25
    Dynavax Technologies Corporation – Pipeline Products by Route of Administration                                      27
    Dynavax Technologies Corporation – Pipeline Products by Molecule Type                                                28
Dynavax Technologies Corporation – Recent Pipeline Updates                                                               29
Dynavax Technologies Corporation – Locations And Subsidiaries                                                            31
    Head Office                                                                                                          31
    Other Locations & Subsidiaries                                                                                       31
Financial Deals Landscape                                                                                                32
    Dynavax Technologies Corporation, Deals Volume Summary, 2004 to YTD 2011                                             32
    Dynavax Technologies Corporation, Deals Summary By Region, 2004 to YTD 2011                                          33
    Dynavax Technologies Corporation, Deals Summary, 2004 to YTD 2011                                                    34
    Dynavax Technologies Corporation Detailed Deal Summary                                                               35
         Acquisition                                                                                                     35
         Dynavax Technologies Acquires Symphony Dynamo From Symphony Capital Partners                                    35
         Dynavax Acquires Rhein Biotech From Crucell                                                                     37
         Venture Financing                                                                                               39
         Fluidnet Secures $6.4 Million In Series A Financing                                                             39
         Equity Offering                                                                                                 40
         Dynavax Technologies Completes Public Offering Of $2.3 Million                                                  40
         Dynavax Completes Private Placement Of $15 Million                                                              42
         Dynavax Completes Public Offering Of $31 Million                                                                44
         Dynavax Completes Public Offering Of $36 Million                                                                46
         Dynavax Completes Initial Public Offering Of $52 Million                                                        48
         Dynavax Technologies Extends Research Collaboration With AstraZeneca                                            50
         GlaxoSmithKline Enters Into An Agreement With Dynavax Technologies                                              51
         AstraZeneca Enters Into An Agreement With Dynavax                                                               52
         Dynavax Technologies Enters Into Co-Development Agreement With Riken                                            53
         Dynavax Technologies Terminates License And Development Agreement With UCB Farchim                              54
         Licensing Agreements                                                                                            55
         Merck Enters Into Licensing Agreement With Dynavax Technologies                                                 55
         Dynavax Technologies Enters Into License Agreement With Coley Pharmaceutical                                    57
         UCB Enters Into Licensing Agreement With Dynavax Technologies                                                   58
         Merck Terminates Licensing Agreement With Dynavax                                                               59
Appendix                                                                                                                 60
    Methodology                                                    
								
To top